Icon

Symbicort - (0.08,0.16mg/inh; 0.0045mg/inh, Aerosol, Metered)

Budesonide; Formoterol Fumarate dihydrate (0.08mg/Inh), (0.16mg/Inh) Astrazeneca
0.08,0.16mg/inh; 0.0045mg/inh, Aerosol, Metered
Less Than $1000 mn
Less Than 5
Less Than 5
More Than 5
None
Less Than 5
Less Than 5
Indicated for the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Yes
***** ** ***. ******* **** ***** * ******* *******, *********** **** ** *******. **** **** ***** **** ** *** *** *********. ** ****** **** **** **** *** ***** **** ****** ** ***** ****. *****, *********** ******* **** ****, ***** *** ***** ** ********** *** *** *****. *****, * ********* ** ******* ** ***** ** *********** *** ******* *****, **** ***** ********* *** ******* '***, '***, '***. ********* ** ********* ********* **** ** *****'* **** ******** ** *** ******* **** **** **** (*.* ****** ** ******* '***, '***, '***)
Symbicort Patent 1 Patent 2 Patent 3 Patent 4 Patent 5 Patent 6 Patent 7 Patent 8 Patent 9 Patent 10 Patent 11 Patent 12
***** ******* ***** *** ** ** *** ********* *** ********* **** ** ** ****** ***** **** ** ** *** ********* *** ********* **** ** ** *** ********* *** ********* **** ** **
**** ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* ******* *** *********
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
***** *** \ *** ***** **, **** ******* ***** ******* *** ** ** ******** ******** ** *** **, ****
**** *** \ ** ***** **, **** ******* **** ***** ***-**** ***********
  1. *** **, **** : ***** ******* *********** ***** *** **** ** **** ******* ‘***(**** **, ****), '*** ( **** **,****), *,***,*** ( **** **,****), *** *,***,*** (*** **,****)
  2. *** **, **** : *********** ***** * **** ******* ***** ** ******** ***** ** ******** ******** ** **** ********.
  3. *** **, **** : **** ******* *********** ***** *** **** ** **** ******* ‘***(**** **, ****), '*** ( **** **,****), *,***,*** ( **** **,****), *** *,***,*** (*** **,****)
  4. *** **, **** : ************ ***** * **** ******* **** ** ******** ***** ** ********.
  5. *** **, **** : *********** ***** * **** ******* **** ** ******* *******,******* ,*******(**** **,****) *** ******* (*** **,****)
  6. *** **, **** : ********** *** ********* **** ***** *** ** *******
  7. *** **, **** : *********** ***** ** ******* ********* ******* ***** ** ******* '***, '***, '***, '***, '***
  8. *** *, **** : *********** ******* **** ****. ***** *** ***** ** ********** *** *** *****.
  9. *** *, **** : *********** ******* **** *****. ***** *** ***** ** ********** *** *** *****.
  10. *** *, **** : * ********* ** ******* ** ***** ** *********** *** ******* *****, **** ***** ********* *** ******* '***, '***, '***. ********* ** ********* ********* **** ** *****'* **** ******** ** *** ******* **** **** **** (*.* ****** ** ******* '***, '***, '***)
  11. *** **, **** : *********** **** ***** ** ****** '*** (**** **,****).
  12. *** *, **** : *** ******** ***** (**) ***** ****** '*** ** ** *******. ***** **** *** ** **** ******. *********** ******** **** ********* ** *** ******* *******.
  13. *** **, **** : ***** **** ** ** **** ****** '*** *** ******** **** ******** ** *** **
  14. *** *, **** : ***** ********* ***** ** ****** ********* ****** '*** *** *********** ********* ****** ********* '***. ** ******, *** ********* ** ********** ** ****** '*** *** **** **** *******. **** ** * *** *** *****, *** ** ****** **** ***** **** ****** ****** *** ****.

Download ParaIV Report


Download ParaIV Detailed Report


To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.